NMN supplements: what the human trials show

Search interest in NMN supplements is large. The human evidence is not. This page covers the human trials and the regulator letters. There is no ranking and no star rating.

Where US law stands

On December 2, 2025 the FDA wrote to a notifier for NMN new-dietary-ingredient notifications 1240 and 1247. The letter says that on September 29, 2025 the agency responded to a citizen petition from the Natural Products Association and the Alliance for Natural Health, changed one part of its reading of the 'race to market' clause, and determined that NMN is not excluded from the dietary-supplement definition. The December letter sets aside a November 2022 letter that had said NMN was excluded, and it reinstates the earlier responses to those two notifications. A copy of the September petition response, hosted by the American Herbal Products Association under a file name 25_0930, gives the reasoning. The December 2, 2025 FDA letter dates the decision as September 29, 2025.

Not excluded is not the same as 'anything goes'. The petition response still treats NMN as a new dietary ingredient. Firms generally need a new dietary ingredient notification unless they are covered by one that already exists for that ingredient from the same manufacturer. The December 2025 letter reinstates two earlier responses, for notifications 1240 and 1247, linked to SyncoZymes. A different manufacturer does not automatically inherit that paperwork. Structure/function claims still cannot become disease claims. The FDA disclaimer on a supplement label does not prove the claim. The Federal Trade Commission can look at whether a longevity or diabetes claim is substantiated. An NDIN acknowledgement is not FDA approval of a health effect.

What the human trials show

NMN means nicotinamide mononucleotide. It is one step in the chemistry that makes NAD, a coenzyme used in everyday cell metabolism. Raising NAD in a blood test is not the same thing as living longer, and it is not a disease treatment. Only two small human trials are cited, so the evidence stops there.

Yoshino and colleagues published a 10-week randomized, double-blind trial in Science in 2021. Twenty-five postmenopausal women with prediabetes, who were overweight or obese, took 250 mg of NMN a day or placebo. Muscle insulin sensitivity during a clamp was about 25 percent higher after NMN than before it, and it did not change after placebo. Muscle insulin signaling increased after NMN. Body composition, blood pressure and lipids did not show a weight-loss story. No adverse events were reported, and standard blood tests stayed unremarkable. This is an early finding in 25 people with prediabetes. It does not show that NMN treats diabetes, and it does not tell a healthy 30-year-old what will happen to them.

Yi and colleagues randomized 80 healthy middle-aged adults to placebo or 300 mg, 600 mg or 900 mg of NMN daily for 60 days. All 80 finished. Blood NAD rose at day 30 and day 60 in each NMN arm versus placebo, with the higher doses higher still. Six-minute walk distance increased more than placebo. HOMA-IR, a rough insulin-resistance number, was not different from placebo at day 60. The investigators reported no safety signal on the events and labs they monitored. A biological-age calculator differed from placebo. That output is a model, not a birthday. The paper's introduction refers to animal lifespan data. The human study did not follow anyone long enough to speak about lifespan.

The part that is reasonably repeatable in these papers is a rise in blood NAD over one to two months. One small trial found a muscle insulin-sensitivity change in a specific group of women at 250 mg a day. Walking distance changed in the larger, still short, Yi trial. Longevity, diabetes treatment, and multi-year safety are not established. EFSA's 2026 opinion judged one specified NMN safe at up to 300 mg a day for adults who are not pregnant or lactating. Safety is not efficacy, and that opinion is not an FDA finding.

Amounts the studies used

250 mg a day for 10 weeks in Yoshino. 300, 600 or 900 mg a day for 60 days in Yi, with the authors describing 600 mg as the point where NAD and walking gains looked strongest. EFSA looked at a proposed maximum of 300 mg a day of one high-purity synthetic β-NMN. None of those numbers is a personal dose. NMN is not an essential nutrient with a recommended dietary allowance. Do not read a trial protocol as instructions.

Side effects in the studies

Yoshino reported no adverse events in 10 weeks at 250 mg. Yi reported no safety issues at up to 900 mg for 60 days on the checks they ran. EFSA did not raise a genotoxicity concern for the ingredient it assessed, did see reproductive-organ findings in a 90-day rat study, and excluded pregnant and lactating women from the proposed use. Sixty days in healthy adults is not a lifetime. People with cancer, people who are pregnant, and people on complex medicine regimens were not the populations cleared by these papers. Ask a clinician. Call 911 in an emergency.

Limits of the evidence

The precursor comparison is a separate page. Yoshino's group was 25 postmenopausal women with prediabetes, followed for 10 weeks. Yi's group was 80 healthy middle-aged adults, followed for 60 days. Neither paper followed people for years, and neither enrolled pregnancy, cancer treatment, or a broad range of prescribed medicines. EFSA's opinion, which is not a US licence, still kept pregnant and lactating women out of the use it assessed. That exclusion is part of the safety file. A rise in blood NAD, or a change in a clamp or a walk, is not a disease claim and not a personal dose. Call 911 rather than a supplement company if you are acutely unwell. A clinician licensed in your state is the person who can look at your other medicines.

Keep the population and the duration next to any number you remember. Twenty-five women for ten weeks, and eighty adults for sixty days, are early human studies. A rise in a blood measurement, a clamp result, or a walk distance is not a promise about disease, lifespan, or a bottle on a shelf. Nothing here is a personal dose. Call 911 in an emergency, and talk with a clinician licensed in your state before you start or stop a supplement or a medicine. Twenty-five women and eighty adults are early studies, not a personal dose and not a ranking of bottles. Call 911 in a medical emergency.